**Educational Sessions**

**The transplant algorithm in lymphoma (1E)**
Chairs: P. Dreger, Germany; M. Gomes da Silva, Portugal
- High grade lymphoma: N. Milpied, France
- Role of stem cell transplantation in patients with follicular lymphoma: S. Montoto, UK
- Hodgkin disease: A. Sureda, Spain

**The transplant algorithm in acute leukemia (2E)**
Chairs: B. Savani, USA; J.E. Guimarães, Portugal
- ALL: A. Nagler, Israel
- De novo AML: A. Rambaldi, Italy
- Secondary AML and MDS: N. Kroger, Germany

**Transplant in elderly or fragile myeloma patients (3E)**
Chairs: L. Garderet, France; F. Leal da Costa, Portugal
- Transplant in patients with kidney dysfunction: J. Blade, Spain
- Salvage transplant for relapse: G. Cook, UK
- Transplant in elderly and frail myeloma patients: M. Mohty, France

**Transplant in autoimmune disorders (4E)**
Chairs: J. Snowden, UK; A. Botelho de Sousa, Portugal
- Transplant for multiple sclerosis: R. Burt, USA
- Transplant for Crohn's disease: M. Rovira, Spain
- Transplant for lupus: D. Farge, France

**The transplant algorithm in bone marrow failures (5E)**
Chairs: M. Abecasis, Portugal; J. Passweg, Switzerland
- Severe aplastic anemia: to transplant or not to transplant? A. Risitano, Italy
- Inherited marrow failure disorders: C. Dufour, Italy
- PNH: R. Peffault de Latour, France

**Pharmacologic pre-transplant interventions to enhance disease control (6E)**
Chairs: A. Bazarbarchi, Lebanon; C. Solano, Spain
- Immune check-point inhibitors in lymphomas: M. Perales, USA
- Bispecific antibodies in ALL: H. Einsele, Germany
- Options in AML: J. Esteve, Spain

**Pharmacologic post-transplant interventions to prevent relapse (7E)**
Chairs: Jordi Esteve, Spain; Isabelina Ferreira, Portugal
- FLT3 inhibitors: A. Bazarbachi, Lebanon
- HDAC inhibitors: G. Bug, Germany
- Hypomethylating agents: C. Craddock, UK

**Chronic GVHD prevention and therapy (8E)**
Chair: Antonio Campos, Portugal
- Diagnosis and grading of chronic GVHD: S. Pavletic, USA
- First line therapy of chronic GVHD: H. Greinix, Austria
- Therapy of refractory chronic GVHD: A. Olivieri, Italy
Acute GVHD prevention and therapy (9E)
Chairs: G. Basak, Poland; N. Miranda, Portugal
  o Diagnosis and grading of acute GVHD: T. Rutuu, Finland
  o Pharmacologic prevention of acute GVHD: J. Perez Simon, Spain
  o Therapy of acute GVHD (first line and refractory): E. Holler, Germany

Late post-transplant complications (10E)
Chair: J.M. Moraleda, Spain
  o Bone complications: M. Arat, Turkey
  o Neuropsychological complications: A. Tichelli, Switzerland
  o Secondary malignancies: B. Savani, USA

Rare post-transplant complications (11E)
Chairs: Rafael Duarte, Spain; F. Campilho, Portugal
  o Transplant-related mortality: the elephant in the room: F.B. Petersen, USA
  o Cyclophosphamide and other related acute cardiac complications: R. Dulery, France
  o Pathophysiology and management of iron toxicity during and after transplantation: T. De Witte, The Netherlands

Drug and cell therapy for infections (12E)
Chairs: G. Teixeira, Portugal; R. de la Cámara, Spain
  o CMV management: P. Ljungman, Sweden
  o Multidrug-resistant bacteria in HSCT patients: D. Averbuch, Israel
  o Rare viruses (ex. HHV6, BKV, Adenovirus, etc): E. Brissot, France

HSCT for inherited diseases (13E)
Chairs: M. Gonzalez Vicent, Spain; M. Aljurf, Saudi-Arabia
  o Thalassemia: F. Locatelli, Italy
  o Sickle cell disease – what curative options do we have? S. Corbacioglu, Germany
  o HLH: A. Lankester, The Netherlands

Results of haplo-identical transplantation (1W)
Chairs: N. Miranda, Portugal; J.L. Diez-Martin, Spain
  o In non-malignant hematological disease: X. Huang, China
  o In refractory AML: M. Mohty, France
  o In ALL: D. Blaise, France

Haplo-identical transplantation versus other donor sources (2W)
Chairs: I. Ferreira, Portugal; M. Rovira, Spain
  o AML: A.L. Ruggeri, France
  o Haplo-identical SCT in Hodgkin lymphoma: M. Kwon, Spain
  o ALL: J. Cornelissen, The Netherlands

Translational research in GVHD (3W)
Chairs: O. Penack, Germany; J. Lacerda, Portugal
  o The role of micro RNAs and kinases: R. Zeiser, Germany
  o Role of the endothelium: T. Luft, Germany
  o Role of invariant NKT cells: F. Malard, France

Fertility and sexuality – Joint Session with the Nurses Program (4W)
Chair: C. Pereira, Portugal
  o Fertility preservation in adults: M.M. Dolmans, Belgium
  o Management of sexual dys functioning: TBA
  o Fertility preservation in children: K. Jahnukainen, Finland

Workshops
Challenging situations after allogeneic transplantation (5W)
Chairs: H. Schoemans, Belgium; C. Martins, Portugal
  o Enteral nutrition after transplant: I. Yakoub-Agha, France
  o Vascular access: S. Cesaro, Italy
  o Transfusion support in case of refractoriness to platelets: H. Schrezenmeier, Germany

Management of some rare complications post-transplant (6W)
Chairs: T. Ruutu, Finland; A. Bermúdez, Spain
  o TMA: E. Carreras, Spain
  o IPS: A. Bergeron, France
  o Poor graft function without rejection: A. Bacigalupo, Italy

Cellular therapy for GVHD modulation (7W)
Chairs: H. Greinix, Austria; J.A. Pérez Simon, Spain
  o Mesenchymal cells: F. Sanchez-Guijo, Spain
  o B Cells: J. Ritz, USA
  o Regulatory T cells: J. Lacerda, Portugal

Questions in aplastic anemia (8W)
Chairs: J. Marsh, UK; M. Abecasis, Portugal
  o Immunosuppressive therapy or SCT front line therapy: C. Dufour, Italy
  o Eltrombopag: making stem cells great again: D. Townsley, USA
  o SCT in older patients with SAA: TBA

Optimizing Quality of Life during and after Hematopoietic Cell Transplant (9W)
Chairs: F. Schulz-Kindermann; Germany, C. Pinho Vaz, Portugal
  o Patient-reported outcomes measures: A. Barata, Spain
  o QoL over time after transplantation: K. Syrjala, USA
  o Interventions to improve QoL after transplantation: Z. Peric, Croatia

Monitoring prior and post-transplant (10W)
Chairs: J. Sanz, Spain; M. van den Brink, USA
  o Strategies to enhance post-transplant immune reconstitution: M. van den Brink, USA
  o MRD monitoring in AML and impact in the pre- and post-transplant settings: M. Heuser, Germany
  o NGS-driven decisions in transplant for MDS: S. Ogawa, Japan

Plenary Sessions

Immunotherapy before and after transplantation (1P)
Chairs: A. Campos, Portugal; A. Madrigal, UK
  o Adoptive T cell therapy and stem cell transplantation – impact of timing: J. Barrett, USA
  o Innate T Cells: J. Kuball, The Netherlands
  o HSV-TK cells adoptive therapy: F. Ciceri, Italy

The microbiota forum (2P)
Chair: M. Mohty, France
  o Microbiota disruption and transplant outcome: TBA
  o Modulation of chemotherapy activity by the microbiome: TBA
  o Impact of the microbiome on acute GVHD: G. Hill, Australia

Access to innovations: the new challenges (3P)
Chairs: M. Abecasis, Portugal; D. Caballero, Spain
  o Outcomes and benchmarking: the next frontier in HSCT: R. Duarte, Spain
  o Modern drugs and cost-effectiveness: where are we going? J.L. Harousseau, France
  o ATMP – the challenges: C. Chabannon, France
How Do I … Sessions

Select the donor for my patient (HD1a): E. Carreras, Spain
Select the best haploidentical donor (HD1b): D. Blaise, France

Optimizing stem cell mobilization (HD2a): C. Chabannon, France
Optimizing the outcomes of cord blood stem cells (HD2b): A. Ruggeri, France

Managing severe aplastic anemia (HD3a): L. Yañez, Spain
Managing pure red cell aplasia (HD3b): A. Tichelli, Switzerland

Diagnosis and management of toxoplasmosis and pneumocystis jiroveci (HD4a): R. de la Cámara, Spain
Diagnosis and management Listeriosis and Nocardiosis (HD4b): E. Brissot, France

Meet the Expert Sessions

Choice of the donor in haplo transplants (MTE1): D. Blaise, France
Management of steroid-refractory acute GVHD (MTE2): E. Holler, Germany
Management of liver dysfunction after transplant (MTE3): T. Ruutu, Finland
Transplant indications in CML (MTE4): M. Abecasis, Portugal
Maintenance therapy in Hodgkin disease (MTE5): A. Sureda, Spain
Options in refractory ALL in adults (MTE6): S. Giebel, Poland
Allogeneic transplantation for pediatric ALL (MTE7): C. Peters, Austria
Second allo-HSCT (MTE8): F. Baron, Belgium
HSCT for primary immunodeficiencies – how and when? (MTE9): A. Gennery, UK
Autologous transplant for scleroderma (MTE10): D. Farge, France
Management of fungal infections: 2018 (MTE11): R. Duarte, Spain
Treatment of Richter syndrome (MTE12): P. Dreger, Germany
Autologous HCT in amyloidosis (MTE13): M. Rovira, Spain
Immune cytopenias after HSCT (MTE14): J. Passweg, Switzerland
Transplant in myelofibrosis (MTE15): N. Kröger, Germany
Allogeneic transplantation in the elderly (MTE16): G. Basak, Poland
How I treat relapse after allogeneic SCT in children (MTE17): P. Bader, Germany
How to write a good manuscript, abstract or grant (MTE18): H. Lazarus, USA

Special Sessions

Social Media session
Chairs: M. Mohty, France; N. Majhail, USA
  o Basic guidance and tips on how to use Twitter at a medical conference: N. Majhail, USA
  o Case study on how the use of Twitter and other social media platforms is an asset to grow your own career: K. Ghanem, Lebanon
Panel discussion: Focusing on how hematologists and other HCPs can appropriately interact with patients on Twitter while maintaining privacy and ensuring ethical standards
Moderator: N. Majhail, USA
Panelists:
  M. Mohty, France
  J. Boelens, The Netherlands
  M.A. Perales, USA
  C. Chmielewski, USA

How to get published?
Session leaders:
  J.V. Melo, Australia
  H. Lazarus, USA
  M Mohty, France
Joint Sessions

EBMT global collaborations: East and West raising the bar together
Chairs: M. Mohty, France; N.C. Gorin, France; M. Abecasis, Portugal
  o The sickle cell connection: B. Simões, Brazil
  o Dynamics of HSCT in Latin America: G. Jaimovich, Argentina
  o Collaboration among HCT societies/outcome registries – Asia-Pacific perspectives: S. Okamoto, Japan
  o Biological characteristics of leukemia relapse after hematopoietic stem cell transplantation and immunotherapy: H. Huang, China

Cell Therapy Day

Introduction to the 7th edition of the Cell Therapy Day: C. Bonini, Italy

Session 1: Donor recruitment & Donation
Chairs: J. Halter, Switzerland; H. Trindade, Portugal
  o Streamlining the search for related and unrelated donors: C. Lemarié, France
  o Choosing wisely. Criteria to help in identifying the best available haplo-identical donor: F. Malard, France
  o Off-label use of plerixafor in healthy donors: N. Worel, Austria

Session 2: Cell procurement & processing
Chairs: S. Roncon, Portugal; P. Perseghin, Italy
  o Impact of apheresis collections on subsequent manufacturing of immunocellular products: A. Bersenev, USA
  o New cryoprotectants – focusing on haematopoietic stem cell products: J. Dyrendom Svalgaard, Denmark
  o Manufacturing of T-cells with anti-infectious activities (ADV, CMV, EBV) by an academic facility serving French transplant programs: an illustration of the hospital exemption: D. Bensoussan, France

Session 3: Joint EBMT - CARAT Session
Chair: C. Chabannon, France
  o Quality vs quantity: what’s more important in CAR T-cells? A. Bondanza, Italy
  o CARAT: Enabling technologies for CAR therapies: A. Kaiser, Germany
  o Balancing safety and efficacy of CAR T-cells: G. Dotti, USA

Session 4: The EBMT Legal and Regulatory Affairs Committee special session
Chairs: J. Kuball, The Netherlands; R. Piteira, Spain & C. Bollard, USA
  o Presentation of the EBMT LRAC: E. McGrath, Spain
  o The EuroGTP II project: E. Trias, Spain
  o How can we facilitate the delivery of advanced therapies to patients? M. Papadaki, UK

Paediatrics Day

Current Transplant Concepts in Children with AML (PDWP Session)
Chairs: P. Bader, Germany; J.-H. Dalle, France
  o Indications and strategies for transplant in CR1 and CR2: F. Locatelli, Italy
  o Current transplant approaches in children with AML in France: J.H.-Dalle, France
  o Is there an optimal conditioning regimen? M. Sauer, Germany
  o Supportive Care and Complication: Results of the workshop for Supportive Care of PDWP: M. Ifversen, Denmark
Panel Discussion: Qupo vadas – Transplant in children with AML
Panelists:
  P. Bader, Germany
  B. Gibson, UK

Paediatric Educational Session: Acute lymphoblastic Leukemia – Detection and Prevention of Relapse
Chairs: X. Duarte, Portugal; K. Vettenranta
  o Detection of impending relapse in children with leukemia after allo SCT: P. Bader, Germany
  o Strategies to prevent relapse: from DLI to monoclonal antibodies: A. Balduzzi, Italy
  o Cellular therapy with CAR-T-cells to prevent relapsed ALL: P. Amrolia, UK
Psy Day

Psy 1: Welcome

Psy 2: Opening
Chair: M. Abecasis, Portugal; N. Miranda, Portugal; A. Ribeiro, Portugal & C. Nave, Portugal
- Introduction: S. Moreira, Portugal

Psy 3: Keynote Opening Lecture
Chair: S. Moreira, Portugal
- Patient-Centered Care: A. Barata, Spain

Psy 4: Psychosocial Support - Part One - To Patient
Chair: A. Barata, Spain
- Psychological Evaluation of Patients Undergoing Bone Marrow Transplantation: S. Almeida, Portugal
- Evaluation of an Exercise Intervention to Improve Cognition After Allogeneic Stem Cell Transplantation - The CaSpo Study: A. Scherwath, Germany

Psy 5: Psychosocial Support - Part Two - To Family
Chair: A. Scherwath, Germany
- Psychosocial Needs of the Caregivers: A. Ribeiro, Portugal
- GACIDHO: Support Group to the Informal Caregivers of the Hemato-Oncologic Patient: L. Calado, Portugal
- The emotional impact of donating bone marrow to a sibling during adolescence: J. Elfer, UK

Psy 6: Psychosocial Support - Part Three - To Staff
Chair: A. Polomeni, France
- A Psychological View of the Bone Marrow Transplant Team: F. Barbosa, Portugal
- Helping Our Colleagues do What They Like Best: The UK Experience of Psychological Skills Training and Supervision for Nurse Specialists: A. King, UK

Psy 7: Keynote Closing Lecture
Chair: F. Schulz-Kindermann, Germany
- Teams’ difficulties in HSCT setting – psychological and ethical issues: A. Polomeni, France

Working Party Sessions

Complications and Quality of Life (CQLWP) Session
Chair: G. Basak, Poland; Z. Peric, Croatia
- Introduction to WP and its activities: G. Basak, Poland
- Complications of haploidentical HCT with posttransplant cyclophosphamide - prospective non-interventional study: G. Basak, Poland
- Schistocyte quantification for the diagnosis of transplant-associated microangiopathy (TAM): I. Moiseev, Russia
- Incidence, severity, management and outcome of SOS/VOD after alloHCT - prospective non-interventional study: T. Ruutu, Finland
- Association between pre-HCT uric acid concentration and GvHD - prospective non-interventional study: O. Penack, Germany
- Impact of ATG on outcome of patients after RIC for allogeneic HCT - retrospective study: H. Greinix, Austria
- Autoimmune complications of alloHCT - EBMT survey: K. Hashaishi, UK
- Investigation and management of bone density after HCT – EBMT survey: TBA
- Outcome of patients with secondary malignancies after HCT - retrospective study: A. Tichelli, Switzerland

Acute Leukemia (ALWP) Session: Immunotherapy for prevention and treatment relapse after SCT in Acute Myeloid Leukemia
Chair: A, Nagler, Israel, S. Giebel, Poland & C. Schmid, Germany
- Opening Comments: A. Nagler, Israel
- Pathogenesis of leukemic relapse post Allo: J. Sierra, Spain
- Novel strategies to activate NK cells and make them antigen-specific: J. Miller, USA
- Unmanipulated donor T-cells – clinical outcome: C. Schmid, Germany
- Immunecheckpoint inhibitors: A. Nagler, Israel
- Treating AML with CAR-T cell and antibodies: G. Ehninger, Germany
- Summary and Questions: A. Nagler, Israel

**Autoimmune Diseases (ADWP) Session**

Chairs: J. Snowden, UK; T. Alexander, Germany
- Summary of ADWP database activity: J. Snowden, UK; T. Alexander, Germany
- HSCT for systemic sclerosis – patient selection and future perspectives: D. Farge, France
- Mesenchymal stem cells open a window on cell therapy in systemic sclerosis: N. del Papa, Italy
- Polish experience of HSCT for autoimmune diseases: K. Kirgizov, Russia
- Chinese experience in autologous HSCT with special focus on systemic lupus erythematosus: TBA

**Lymphoma (LWP) Session**

Chair: S. Monoto, UK

Introduction: S. Montoto, UK

Highlights of the LWP activity: S. Robinson, UK
LWP Educational Course 2018: A. Sureda, Spain
Presentation of the Jian-jian Luan award winner: S. Montoto, UK
Lecture of the Jian-jian Luan award abstract: TBA

LWP keynote debate: Should we choose a halpo over a 10/10 donor in NHL?
- No: S. Montoto, UK
- Yes: N. Schmitz
- Discussion: L. Castagna, Italy

Concluding remarks: S. Montoto, UK & S. Robinson, UK